In the new logo with photos of generic looking vials, the Libre CGM and three men in the 50s playing basketball

In the News.. A partner for a T1D prevention drug, expanding CGM Medicare coverage, the worst age for T2D outcomes, and more!

[podcast src=”https://html5-player.libsyn.com/embed/episode/id/24681774/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/3e9ccc/” width=”100%” scrolling=”no” class=”podcast-class” frameborder=”0″ placement=”top” primary_content_url=”http://traffic.libsyn.com/diabetesconnections/Ep_519_Final_In_the_News.mp3″ libsyn_item_id=”24681774″ height=”90″ theme=”custom” custom_color=”3e9ccc” player_use_thumbnail=”use_thumbnail” use_download_link=”use_download_link” download_link_text=”Download” /]It’s It’s “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: Provention Bio hopes to get FDA approval of Teplizumab next month and partners with Sanofi on this T1D prevention…